Catalyst Brief

← Calendar

Readoutin 76d

Acerta Pharma BV — acalabrutinib

Phase 3 primary completion: A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312).

Date
Feb 2027
Type
Readout
Indication
Diffuse Large B-Cell Lymphoma

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.

More from Acerta Pharma BV

  1. Apr2027